Published on

A large-scale clinical trial conducted by the National Cancer Institute found that one dose of an HPV vaccine is just as protective against infection as the traditional 2-dose regimen. The randomized study, which enrolled more than 20,000 girls aged 12 to 16 years, compared the effectiveness of 1 and 2 does of the bivalent Cervarix (GlaxoSmithKline) vaccine and the 9-valent Gardasil 9 (Merck) vaccine. Participants were assigned to receive either dosing regimen, and both groups were monitored every 6 months over a 5-year period. The results demonstrated that 1 dose of either vaccine provided comparable protection to 2 doses with vaccine efficacy exceeding 97%. Additionally, there were no significant differences in persistent HPV 16/18 infections between the groups. These findings were shared in advance of a scheduled vote by the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices, which may ultimately recommend a single-dose schedule for HPV, according to meeting coverage from MedPage Today. 

Faster and easier for patients: Simplifying the vaccination regimen could help boost uptake, particularly in low-resource settings, while increasing protection against several types of cancer, including cervical, anal, penile, and certain head and neck cancers.

Continue Reading

One Dose of HPV Vaccine Could Be Enough
Log In